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Caraway (Carum carvi L.), a potent medicinal plant, is traditionally used for treating obesity. This study investigates the weight-
lowering effects of caraway extract (CE) on physically active, overweight and obese women through a randomized, triple-blind,
placebo-controlled clinical trial. Seventy overweight and obese, healthy, aerobic-trained, adult females were randomly assigned to
two groups (𝑛 = 35 per group). Participants received either 30mL/day of CE or placebo without changing their diet or physical
activity. Subjects were examined at baseline and after 90 days for changes in body composition, anthropometric indices, and clinical
and paraclinical variables.The treatment group, compared with placebo, showed a significant reduction of weight, bodymass index,
body fat percentage, and waist-to-hip ratio. No changes were observed in lipid profile, urine-specific gravity, and blood pressure
of subjects. The results suggest that a dietary CE with no restriction in food intake, when combined with exercise, is of value in
the management of obesity in women wishing to lower their weight, BMI, body fat percentage, and body size, with no clinical side
effects. In conclusion, results of this study suggest a possible phytotherapeutic approach for caraway extract in the management of
obesity. This trial is registered with NCT01833377.
1. Introduction
Proper nutrition is necessary to keep the body healthy and
functioning normally. The addition of extra calories in the
diet induces fat accumulation, leading to overweight and obe-
sity. According to the World Health Organization (WHO),
excess body weight and obesity are recognized as a body
mass index (BMI) greater than 25 kg/m2. According to this
report by WHO, “globesity,” as a foodborne illness, is a rapi-
dly growing global problem, which is maximizing the risk of
various health problems, such as type 2 diabetes, cardiovas-
cular diseases (CVD), musculoskeletal disorders, and cancer.
Overweight and obesity are associated with high morbidity
and mortality, resulting in considerable health care costs and
other economic and social impacts on the society. Since 1980,
obesity has almost doubled worldwide and is recognised as
one of the leading causes of death. In 2008, over 1.4 billion
adults, predominantly women, were overweight or obese.
Finally, more people die because of being overweight and
obese than those who are underweight, and this disease
state is the fifth main reason for mortality and the sixth for
health problems globally. Management of obesity is therefore
a public health necessity [1–5].
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Obesity is associated with multiple macro- and microen-
vironmental factors. It is manageable by several differ-
ent approaches, including pharmaceutical drugs, traditional
medications, and surgery. Of these approaches, the use of
medicinal plants is increasingly popular and is preferable
to conventional chemotherapeutic methods [6, 7]. Early
indigenous people faced with various forms of illness and
health problems discovered a wealth of valuable healing
agents in their local flora. There are a frequently number of
potential advantages linked to the use of medicinal plants,
including accessibility, safety, effectiveness, affordability, reli-
ability, and acceptability, typically with minor adverse effects
and lower costs [8]. Moreover, medicinal plants are naturally
available sources with potentially beneficial biological and
pharmacological effects and are easy to consume, whereas
there is still doubt about the other more invasive therapeutic
modalities for obesity, such as surgery [9].
Specific phytochemical constituents present in medicinal
plants may assist in regulating weight and body fat through
modifying metabolic pathways at the molecular level which
are responsible for signalling adipogenesis, lipolysis, and so
forth [10]. Hence, they are able to play multiple roles sim-
ultaneously in a network pharmacology approach to disease
alleviation.
Caraway (Carum carvi L.) is a well-known medicinal
plant, which was traditionally recommended by the great
ancient scientist of the eleventh century Ibn Sina (also
known as Avicenna) for weight loss, and is used widely
for culinary purposes in Asia and Europe [11]. This plant
is from the Apiaceae (formerly Umbelliferae) family and is
used in traditional medicine as a remedy for a range of
health problems, especially stomach ache, burping and flatu-
lence, and intestinal spasms [12–17]. Caraway seeds contain
multiple phytochemical constituents, including fatty acids,
essential oils, and volatile phenolic compounds which are
used in industry and medicine [18–22]. These bioactive
ingredients present in caraway seeds induce a range of differ-
ent biological benefits, including antimicrobial, antioxidant,
anti-inflammatory, and anticancer activities, which offers
promising therapeutic potential to alleviate several human
diseases [23–29].
Previous studies have established an association between
the moderate consumption of caraway-derived metabolites
with a lower incidence of diabetes, dyslipidaemia, hyper-
tension, liver dysfunction, reproductive hormone imbal-
ance, osteoporosis, cancer, gastrointestinal, and inflamma-
tory diseases [13, 30]. In addition, in vitro and in vivo
studies have demonstrated the hepatoprotection and safety
of caraway ingredients for use in pharmaceuticals and food
products [30–32]. A further study showed a plausible, mul-
titargeted, antiobesity effect of caraway on animals through
modifying the gene expressions associated with inflamma-
tion and adipogenesis [33]. Accordingly, this activity of
caraway was examined in a clinical study of overweight
and obese subjects as a dietary intervention, in combina-
tion with physical activity, in a homogenous population
of physically active, adult women selected to evaluate the
reliability of the earlier indications in a formal clinical
environment.
2. Methods
2.1. Study Design and Study Population. The clinical study
reported was a randomized, triple-blind, placebo-controlled,
clinical trial, with a duration of three months, and was
designed and conducted to evaluate the weight-lowering
effect of the caraway seed extract (CE) compared with
placebo. Obese and overweight women with a BMI (body
mass index) of 25–39.9 kg/m2 and ages between 20 and 55
years were eligible for this study. Volunteers were recruited
at a fitness centre in Yazd, Iran, and were doing moderate
aerobics training for 180 minutes/week, with an estimated
energy expenditure of 1000–1200 kcal/week.
Subjects with a history of extreme weight loss through
surgery or abnormal diet and the presence of diagnosed,
severe health problems including hypertension, CVD, dys-
lipidaemia, clinical depression, diabetes mellitus, and thy-
roid diseases, using alcohol, cigarette, or any medication or
supplements which might have an effect on metabolism or
appetite, having a history of allergy to the medicinal plant
extract or placebo products, and also pregnant and lacta-
ting womenwere specifically excluded from the study cohort.
This interventional study was registered with the clinical-
trial.gov protocol registration system with the Protocol no.
NCT01833377 and was approved by theMedical Ethics Com-
mittee of the University of Malaya Medical Centre (UMMC)
on June 20, 2012 (no. 925/15). All of the entered subjects
signed an approved, written consent form at the initiation of
the study.
Nutritional consultation was provided at baseline entry
into the protocol and during the treatment regimen. Partici-
pants were encouraged to follow a healthy lifestyle habit and
were advised not to make any significant changes to their diet
and routine physical activity during the three-month period
of the study protocol.
2.2. Randomization and Blindness. The seventy (70) qualified
and allotted subjects were randomized into two equal-sized
groups of 35-35 subjects through the online randomiza-
tion program (http://www.randomization.com/). Investiga-
tors, subjects, and the data collectors weremasked to the trea-
tment regimens. A statistician, who was not directly involved
in the establishment of the groupings and the design of
the trial, was provided with the codes and the data for
analysis (triple-blind). The bottled CE and placebo samples
were coded by the coinvestigator who was not involved in
the study, and the sample of CE (500mL) or placebo was
provided for the subjects in sealed PET bottles every two
weeks.The eligible study subjects were randomly allocated to
consume either a 30mL sample of the active CE or placebo
product, once a day, 20 minutes before lunch for 3 months.
2.3. Preparation of Herbal Extract and Placebo. The CE
samples obtained from the Baharan Company, Yazd, Iran
(Industrial Ministry License no. 28/1232 and HealthMinistry
License no. 35/10500) were extracted from the seeds of
caraway through steamdistillation. From each 1 kg of caraway
seeds, 10 litres of caraway water extract was produced.
Consequently, the amount of caraway in terms of w/v was
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0.1 (10%). The analysis of the CE sample used in the study
is described below. The placebo was prepared by dissolving
edible caraway essence (Givaudan Flavours Co., Kemptthal,
Switzerland) in drinking water (1% g/L) which was identical
with CE in appearance and flavour. Subjects were provided
withmeasured bottles andwere asked to dissolve 30mLof the
placebo or CE with 30mL of water. Subjects were provided
with brochures with written instructions.
2.4. Assessments and Study Outcomes. The study visits were
conducted two weeks before the beginning of the trial, at
the beginning of the trial (week 0), and every week up to
the end of the three months of treatment. The screening and
data collection were performed by the investigators and a
medical physician. During the intervention, all participants
were examined and checked weekly to ensure that the study
instructions were being followed, and that intake of samples
was occurring according to the regimen. The occurrence of
any probable side effects was recorded by the volunteers.
Body weight loss was the primary study outcome. The
secondary outcomes included changes in body composi-
tion (body fat, body water, and body muscle percentages),
anthropometric indices (BMI, height, waist circumference,
hip circumference, mid-upper arm circumference, and thigh
circumference), serum lipid profile, urine-specific gravity,
systolic and diastolic blood pressure, and pulse rate. Safety
outcomes also included laboratory assessments and vital
signs. In addition, the occurrence of adverse events which
might be related to the treatment was identified by the
investigator and the physician through physical examination.
All measurements were assessed early in themorning with an
empty stomach and were performed at baseline and at week
12.
Body weight was measured within 0.1 kg intervals. Par-
ticipants were weighed in light clothing and without shoes
using a bioelectrical impedance analysis (BIA) machine with
remote control (Beurer digital diagnostic scale, Model BG63,
Ulm,Germany). Other body composition parameters includ-
ing percentages of body fat (%BF), body water (%BW), and
body muscle (%BM) were displayed with 0.1% graduation.
BMI (kg/m2) was calculated based on the folowing formula
BMI = weight/height2.
Anthropometric indices including height, waist circum-
ference (WC), and hip circumference were measured to
the nearest 0.1 cm, using Seca measuring tape. The waist
circumference was measured by placing the measuring tape
at the umbilicus point (the site between the lowest rib and
the iliac crest); hip circumference (HC) was measured at the
maximum circumference over the buttocks (WHO, 2008).
Waist-to-hip ratio (WHR)was then calculated by dividing the
waist and hip circumferences.
2.5. Clinical Assessments. Vital parameters, including blood
pressure and heart rate, were measured by a physician using
a calibrated mercury sphygmomanometer, stethoscope, and
appropriate cuff sizes on the sitting subject’s right arm after
a 10min rest. Systolic, as well as diastolic, blood pressure
was defined according to phase I and phase V Korotkoff
sounds, respectively. Blood and urine tests were conducted at
the reference laboratory of Shahid SadoughiHospital in Yazd,
Iran in the fasting condition. The biochemical parameters
were analysed using the ELITech diagnostics kits (ELITech
Group, Puteaux, France).
2.6. Sample Size Calculation. The required sample size was
calculated using the sample size formula described by Green-
berg et al. [34] with 99% level of confidence, 1% precision,
and with a power level of 90%. The primary variable was
weight, and the sample size was based on a two-tailed 𝑡 test.
The standard deviation of weight in the study population
was anticipated to be 14 kg, which is similar to the weight
measurements obtained from previous studies. According to
this formula, a total sample of 60 subjects (30 subjects in
each group) was required. To enhance the power for iden-
tifying significant differences in weight loss of participants
from baseline compared to the control group and assuming
dropouts and loss to followup during the three-month study
intervention period, 10 extra patients were randomized and
included. Hence, a total of seventy (70) overweight and obese
women with BMI > 25 were recruited for this study.
2.7. Gas Chromatography-Mass Spectrometry (GC-MS) Analy-
sis. Thephytochemical constituents present in CEwere iden-
tified using GC-MS analysis with flame ionization detector
(FID) and extracted by HS-SPME with subsequent hexane
extraction. The capillary gas chromatographic profiles of
the CE constituents were reported as their retention time
compared with the MS of standard compounds [35].
2.8. Statistical Analysis. Values for each subject were stan-
dardized for each dependent variable to remove outliers
using Z-scores, and the normal distribution was tested using
the Kolmogorov-Smirnov test. Student’s 𝑡-test, with a 99%
confidence interval, was applied to identify the significant
differences in values between groups, and the paired 𝑡-test
was used to examine mean differences within each group
during the three-month treatment period [36]. All statistical
analyses were performed using SPSS software version 18.0.0
(SPSS Inc., Chicago, IL, USA), and all data are expressed
as mean ± standard deviation (SD); 𝑃 values less than 0.01
were considered to be significant and equal variances were
assumed.
3. Results
3.1. Demographic and Baseline Features of the Subjects. Of
the 110 overweight women who originally registered for
screening, seventy were deemed eligible to havemet the study
requirements and constraints.The selected subjects were ran-
domised and assigned equally to the CE and placebo groups.
Of the selected overweight women, ten of the subjects—six
in the placebo group and four in the CE group-failed to
complete the study. At the termination of the study, therefore,
sixty of the seventy patients completed the full three months
of treatment.The demographic characteristics of the subjects
in the study are summarized in Table 1. About 54% of the
subjectswere overweight and 46%were obese.Themean (SD)
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Table 1: Demographics of study participants randomized to the placebo or CE groups (𝑛 = 35).
Variables Placebo CE 𝑃 value
Mean ± SD Mean ± SD
Age (years) 37.00 ± 7.90 37.23 ± 9.34 0.91
Height (cm) 158.20 ± 4.90 159.74 ± 6.22 0.25
Weight (kg) 74.88 ± 11.70 75.99 ± 11.84 0.70
Body mass index (BMI, kg/m2) 30.39 ± 4.69 29.24 ± 3.36 0.24
Bone mass (kg) 7.79 ± 1.11 8.05 ± 1.07 0.35
Sleep (hours/day) 7.87 ± 1.61 7.86 ± 1.29 0.97
Physical activity level (PAL, kcal/kg/day) 43.68 ± 2.48 44.39 ± 2.79 0.26
Basic metabolic rate (BMR, kcal/m2/hour) 1474.42 ± 123.46 1488.00 ± 154.43 0.69
Active metabolic rate (AMR, kcal/m2/hour) 2241.42 ± 216.27 2176.57 ± 260.47 0.30
Resting energy expenditure (REE, kcal) 1453.21 ± 133.26 1503.11 ± 127.37 0.15
Total daily energy expenditure (TDEE, kcal) 2236.06 ± 206.93 2308.33 ± 193.17 0.17
Table 2: Measured variables (mean ± SD) at baseline and after the three-month intervention period.
Variables Week 0 Week 12
Placebo (𝑛 = 29) CE group (𝑛 = 31) Placebo (𝑛 = 29) CE group (𝑛 = 31)
Body composition
Weight (kg) 71.96 ± 10.66 76.86 ± 12.24 72.77 ± 10.84 75.0 ± 12.24∗
Body mass index (BMI, Kg/m2) 28.34 ± 2.59 30.69 ± 4.69 28.50 ± 2.80 29.85 ± 4.70∗
Body fat (BF, %) 33.82 ± 2.40 35.43 ± 3.60 34.04 ± 2.47 34.74 ± 3.74∗
Body muscle (BM, %) 31.81 ± 1.27 31.42 ± 1.60 31.75 ± 1.29 31.61 ± 1.60∗
Body water (BW, %) 48.34 ± 1.89 47.16 ± 2.63 48.12 ± 1.78 47.15 ± 2.67
Anthropometric indices
Waist circumference (WC, cm) 91.34 ± 7.33 96.02 ± 10.21 91.21 ± 7.90 89.78 ± 8.64∗
Waist-to-hip ratio (WHR) 0.87 ± 0.04 0.86 ± 0.06 0.87 ± 0.05 0.83 ± 0.05∗
Paraclinical assessments
Diastolic blood pressure (DBP, mmHg) 74.29 ± 6.0 75.48 ± 7.89 70.97 ± 7.60 75.9 ± 6.80
Systolic blood pressure (SBP, mmHg) 111.25 ± 10.33 112.74 ± 10.40 111.25 ± 9.49 113.39 ± 11.21
Heart rate (beats per minute) 75.21 ± 8.70 78.06 ± 9.11 74.46 ± 8.56 77.51 ± 8.11
Lipid profile
Cholesterol (mg/dL) 183.33 ± 22.56 209.33 ± 29.87 190.38 ± 51.9 199.0 ± 25.1
Triglyceride (TG, mg/dL) 121.86 ± 41.49 112.81 ± 35.14 145 ± 50.4 124.43 ± 42.6
High density lipoprotein (HDL, mg/dL) 52.95 ± 9.87 55.90 ± 9.57 51.71 ± 7.7 56.71 ± 10.1
Low density lipoprotein (LDL, mg/dL) 106.73 ± 17.67 123.94 ± 28.65 110.77 ± 41.9 125.77 ± 25.9
Urine test
Urine-specific gravity (USG, g/mL) 1.017 ± 0.006 1.021 ± 0.006 1.018 ± 0.005 1.022 ± 0.006
∗
𝑝 < 0.01 significantly different from baseline compared to placebo.
age, body weight, and BMI of the participants were 37.11 (8.6)
years, 75.43 (11.7) kg, and 29.82 (4.1) kg/m2, respectively. The
average physical activity level of the participants was 44 (2.6)
(kcal/kg/day) with 7.86 (1.4) hours of sleep. No significant
differences of all of these features were observed between the
two groups. At baseline, there were no significant differences
in the body composition, anthropometric indices, clinical
and para-clinical assessments of both groups, except for the
waist circumference which was at the borderline. All of the
participants had abdominal obesity (waist circumference >
88 cm) (Table 2).
3.2. Comparison within and between Groups during theThree-
Month Trial. The changes in variables over the three-month
intervention period for the CE and the placebo groups
are also shown in Table 2. Significant mean weight loss
was observed within the CE group after three months of
treatment, whereas the average weight in the placebo group
was increased. The mean weight loss between the CE group
and placebo group was significant. The mean weight in the
CE group dropped remarkably as compared with the placebo
group. Therefore, this traditional medicine extract probably
has a positive effect on lowering body weight. Similarly,
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Figure 1: Chromatogram of CE infusion extracted by HS-SPME.
Identification of CE volatiles obtained by steamdistillationwith sub-
sequent hexane extraction, including (1) limonene, (2) 𝛾-terpinene,
(3) trans-carveol, (4) carvone, (5) thymol, and (6) carvacrol.
the average BMI and %BF in the CE group were significantly
decreased. In contrast, in the placebo group, these values
increased slightly. Nevertheless, the mean reduction in the
BMI and %BF was significant between the CE group and the
placebo group.
The percentage of body muscle in the CE group showed a
significant increase after intervention. Body water percentage
decreased in both groups and was not significant either
within or between groups. On the other hand, the WC and
WHR were reduced significantly only in the CE group. How-
ever, the level of reduction (cm) in all of the anthropometric
indices was remarkable between groups. There were no
noticeable changes in para-clinical and clinical assessments
with either treatment. According to the outcomes of the study,
CE showed greater efficacy than did placebo for each primary
outcome measure.
3.3. Safety Issues and Adverse Events. No significant changes
were observed for heart rate, systolic and diastolic blood
pressure, lipid profile, and urine-specific gravity between and
within the two groups during the three-month study period.
Of the sixty subjects who completed the study, only the
placebo participants experienced skin allergy to the placebo
product, and no important adverse events were reported
during the physical examinations.
3.4. Detection of Phytochemicals Using GC-MS. The principal
volatile compounds analyzed by GC-MS following extraction
weremostlymonoterpenoids, as shown in the chromatogram
in Figure 1.
4. Discussion
The weight-lowering property of caraway as a known
medicinal plant in Iran was examined in a triple-blind,
placebo-controlled, clinical trial in Iranian overweight and
obese women. Since diet and physical activity are the two
lifestyle principleswhich induce normalweight, subjectswere
selected who were regularly performing aerobic exercises
during the entire period of studywithoutmodifying their diet
and lifestyle habits. The results indicated a moderate effect
of CE on losing weight, without any severe adverse effects.
This finding is consistent with a recent study which reported
data of antiobesity effect of this plant in an animalmodel [33].
Additionally, numerous studies have reported the therapeutic
effects of caraway on different diseases such as diabetes
mellitus, cardiovascular disease (CVD), and hypertension,
which are known as common complications of obesity [37–
39]. Altogether, the results of this study suggest a plausible
phytotherapeutic approach for the use of caraway seed extract
in the management of obesity.
Lowering weight and fat in the subjects in this study may
be related to anti-microbial, anti-inflammatory, and antioxi-
dant activities of caraway caused by some of the constituents
in caraway, such as carvacrol (polyphenol) and unsaturated
fatty acids (UFA) (Figure 2) [19].These bioactive compounds
may balance gut microflora (GM) which help in food diges-
tion and absorption providing intestinal homoeostasis [40].
GMmodulates gene expression in the human body involving
the host physiology and metabolism, such as obesity mecha-
nisms [41]. Carvacrol, together with UFA, inhibits the growth
of pathogenic bacteria, and thus increases the proliferation
of GM [42, 43]. In this process, ingredients probably modify
GM through activating the expression of some specific
genes involved in lipid metabolism inhibiting inflammation
and adipogenesis [33, 44]. The balanced GM also inhibits
infiltration ofmacrophages into obese adipose tissues leading
to disruption in the conversion of preadipocytes to mature
adipocytes, thereby preventing adipocyte differentiation and
adipogenesis [45]. UFAs enhance the oxidation of fatty acids
leading to lipolysis and fat loss [46, 47]. Caraway constitu-
ents also stimulate apoptosis in pre-adipocytes due to their
antioxidant activity. They reduce adipose tissue mass thro-
ugh preventing adipogenesis and enhancing lipolysis in adi-
pocytes [10, 48–50]. Further studies are suggested to inves-
tigate the effects of these potent components in reversing
obesity in overweight and obese women at the molecular
level.
In this study, no changes were observed in the sub-
jects’ body water during the intervention, whereas body
weight and fat mass were decreased, and muscle mass was
increased. However, there were also significant changes in
body composition in the placebo group, which shows that
exercise did not have any interfering and/or synergistic effect
on weight and fat loss. This implies that the favourable
changes in body composition were probably associated with
the bioactive compounds in CE and not necessarily with
the physical activity, although it is recognized that there is
likely a synergistic effect of exercise on weight and fat loss
in the treatment group. It is plausible that the bioproducts
formed during lipolysis were converted into muscle induced
by physical activity, synergistically, and that the decrease in
fat mass and the increase in lean mass are feasibly due to
physiological adaptations to exercise [51–53].
To the best of our knowledge, this is the first clinical study
to evaluate the effects of CE intake on body composition and
anthropometric indices, combined with an exercise program,
and examin to antiobesity effects of CE on overweight and
obese women during a twelve-week intervention. In addition,
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Figure 2: The possible metabolic actions of CE on the human body during weight loss.
this study had three other significant aspects. Firstly, even
though the subjects’ dietary habits were not modified, a
significant weight loss was observed in the CE group, as
compared with the placebo group. Secondly, this study was
a triple-blind clinical trial which enhances the accuracy
of the results and reduces potential bias in the findings.
Some limitations of this study should be acknowledged.
Firstly, these results are limited to an extract of caraway;
therefore, further studies are required to find the anti-obesity
effect of other methods of preparation for caraway seed oil
extract. Secondly, as physical activitymight have a synergistic
effect on lowering weight [54], replicating this study on
subjects without exercise is recommended.Thirdly, since this
study was performed with adult females, in order to have
a homogenous population and more reliable data, studies
on the anti-obesity effects of CE in males, as well as in
obese children, are suggested. Fourthly, in this study, obese
or overweight subjects with medical complications, such
as metabolic syndrome and cardiovascular disease (CVD),
were specifically excluded. Future studies to examine the
weight-lowering effects of caraway on overweight and obese
patients having obesity complications are proposed. Finally,
further studies are suggested to examine these results with
different CE doses in order to establish more accurate dosing
limitations.
5. Conclusions
From the above results and discussion, it can be concluded
that caraway is helpful in the management of obesity because
of its bioactive constituents. Although the mechanism of
action of the active principle(s) remains to be determined
at the molecular level, it is speculated to arise from a
prebiotic effect of CE in the gut through balancing its GM
growth. Efforts to provide information and understanding
about the human use of this medicinal plant and make
to the intake of caraway-containing natural and bioactive
pharmaceuticals a sustainable dietary practice, along with
physical activity, towards a healthy lifestyle, should be
continued.
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